Correlation of HbA1c With Electrophysiological Studies and Gait Performance in Diabetic Polyneuropathy Patients

Sponsor
Shereen Saad Eldin Mohamed Ali (Other)
Overall Status
Recruiting
CT.gov ID
NCT05457192
Collaborator
(none)
65
1
3
21.5

Study Details

Study Description

Brief Summary

This study will be conducted to investigate the relationship between glycosylated hemoglobin (HbA1c) and nerve conduction studies (NCS) with gait performance in patients with DPN. 65 patients with type II DM with moderate polyneuropathy will participate in this study. Glycosylated Hemoglobin (HbA1c) test will be done for each patient by using the Colorimeter device. Nerve conduction studies (NCS) will be performed for each patient by using the electromyography device to confirm the diagnosis of DPN. The neurophysiological functions of peripheral nerves including (The Common peroneal, Tibial, Sural, and Ulnar motor & sensory branches) will be measured. Spatiotemporal gait parameters (stride length, cadence& velocity) for all the patients will be assessed by two-dimension video-based motion analysis (2D).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The current study is to investigate the correlation between glycosylated haemoglobin (HbA1c) with nerve conduction studies (NCS) including amplitudes, conduction velocities &latency with spatiotemporal gait parameters including stride length, cadence& velocity in patients with diabetic polyneuropathy (DPN). The patients will be recruited from the Out- patient clinic of Faculty of Physical Therapy, Cairo University. All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS), and Neuropathy Impairment Score in the lower limbs (NIS-LL). Glycosylated Hemoglobin (HbA1c) test will be done for each patient by using the Colorimeter device. Blood will be collected in a EDTA (3 cm) tube that's attached to the needle. A nerve conduction study will be performed for each patient. Five nerves will be examined in this study including (The common peroneal, tibial, sural and ulnar motor & sensory branches). The Nerve conduction studies involve analysis of specific parameters including amplitude (mv), latency (msec.) and conduction velocity(m/s). The evaluation procedure will be explained to each patient before starting examination. Gait parameters including (stride length, cadence & velocity) will be assessed using 2D video-based motion analysis. The gait will be captured by a digital video camera; (Canon 10 mega pixel - 4x optical zoom, lens 4x15/6.2-24.8mm1:2.7-5.6). The resultant captured film will then be processed using a special software computer program (Adobe premier ver. 6.0).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    65 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Glycosylated Hemoglobin and Its Correlations With Electrophysiological Studies and Gait Performance in Diabetic Polyneuropathy Patients
    Anticipated Study Start Date :
    Jul 1, 2022
    Anticipated Primary Completion Date :
    Oct 1, 2022
    Anticipated Study Completion Date :
    Oct 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Moderate diabetic polyneuropathy (DPN)

    65 patients of both sexes (males & females) with type II DM with moderate polyneuropathy will be included. Patients will be enrolled and assessed for their eligibility to participate in this study. Their body mass index (BMI) will range from 20:30 kg/m2, age will range from 40-60 years, postprandial blood sugar more than 200 mg/dl, duration of diabetic illness five years ago or more and serum Hb1AC will be between 7% and 14%. All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS) (score nine to 11 points), and Neuropathy Impairment Score in the lower limbs (NIS-LL) (The muscle power of the lower limbs will be more than grade 2 and less than grade 4)

    Outcome Measures

    Primary Outcome Measures

    1. The neurophysiological parameters [At baseline for all patients]

      Five nerves will be examined in this study including (The common peroneal, tibial, sural and ulnar motor & sensory branches). Nerve conduction studies (NCS) will be performed by using the electromyography device.

    2. Glycosylated Hemoglobin (HbA1c) level [At baseline for all patients]

      Glycosylated Hemoglobin (HbA1c) test will be done for each patient by using the Colorimeter device. The Blood will be collected in a EDTA (3 cm) tube

    Secondary Outcome Measures

    1. Spatiotemporal gait parameters [At baseline for all patients]

      Spatiotemporal gait parameters for all the patients will be assessed by two-dimension video-based motion analysis (2D).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The diagnosis will be confirmed by Nerve Conduction Studies "NCS".

    • All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS) and Neuropathy Impairment Score (NIS-LL).

    • Body mass index (BMI) will range from 20:30 kg/m2.

    • Age will range from 40-60 years.

    • Postprandial blood sugar more than 200 mg/dl.

    • Duration of diabetic illness five years ago or more and serum Hb1AC will be between 7% and 14%.

    • Able to walk independently with or without walking aids.

    Exclusion Criteria:
    • Patients with type I DM.

    • History of myopathy or neuromuscular diseases.

    • Pregnant females.

    • Alcoholics.

    • History of major cardiac diseases, heavy metal.

    • Other neurological problems as stroke.

    • History of ulcers in the lower limbs, foot deformities or malunion fracture of the lower limbs, and acute nerve root compression or advanced arthritis affecting lower extremity.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Faculty of physical therapy-Cairo University Giza Egypt 12625

    Sponsors and Collaborators

    • Shereen Saad Eldin Mohamed Ali

    Investigators

    • Principal Investigator: Shereen Saad Eldin Mohamed, Lecturer, lecturer of Neurology at faculty of physical therapy-Cairo university

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shereen Saad Eldin Mohamed Ali, Lecturer of physical therapy for Neurology, Cairo University
    ClinicalTrials.gov Identifier:
    NCT05457192
    Other Study ID Numbers:
    • P.T.REC/012/003777
    First Posted:
    Jul 13, 2022
    Last Update Posted:
    Jul 13, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Shereen Saad Eldin Mohamed Ali, Lecturer of physical therapy for Neurology, Cairo University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 13, 2022